🇺🇸 AMGN — Amgen Inc.

Healthcare Compra
← Volver

Precio actual

437,23 USD

Máx. histórico

447,03

10 días

Caída desde máximo

-2,19%

Rango 52 semanas

269,77 – 447,03

Variación hoy

-1,55%

Cierre anterior

444,12

Rango de hoy

435,01 – 441,66

Volumen hoy

1.615.172

Información
Nombre completo
Amgen Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
31.500
PER ⓘ
27,17 (puede no estar actualizado)
Dividend yield
2,27% (puede no estar actualizado)
Precio objetivo analistas
389,69 USD (puede no estar actualizado)
Primera cotización
17/06/1983
Precio actualizado
hace 2 días
Sobre la empresa

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Dividendos repartidos Total últimos 12 meses: 9,9400 USD · Yield: 2,27%
Fecha de pago Importe por participación
12/05/2015 0,7900 USD
10/02/2015 0,7900 USD
10/11/2014 0,6100 USD
12/08/2014 0,6100 USD
13/05/2014 0,6100 USD
11/02/2014 0,6100 USD
12/11/2013 0,4700 USD
14/08/2013 0,4700 USD
14/05/2013 0,4700 USD
11/02/2013 0,4700 USD
13/11/2012 0,3600 USD
14/08/2012 0,3600 USD
14/05/2012 0,3600 USD
13/02/2012 0,3600 USD
15/11/2011 0,2800 USD
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
21/09/2017 188,32 188,96 186,50 186,64 -0,81% 1,31% 2.082.200
20/09/2017 186,08 188,55 185,42 188,17 +0,99% 1,68% 2.685.400
19/09/2017 186,81 187,44 185,81 186,32 -0,08% 0,87% 2.066.100
18/09/2017 187,79 188,56 186,12 186,47 -0,53% 1,30% 2.443.800
15/09/2017 189,66 189,66 186,31 187,47 -1,04% 1,77% 5.349.000
14/09/2017 188,37 191,10 187,81 189,44 -0,14% 1,75% 2.318.400
13/09/2017 189,90 190,94 187,71 189,70 -0,68% 1,70% 3.031.400
12/09/2017 187,00 191,04 186,78 191,00 +2,42% 2,28% 3.894.300
11/09/2017 182,54 186,71 182,54 186,49 +3,24% 2,28% 3.791.200
08/09/2017 180,93 182,66 179,52 180,64 -0,04% 1,74% 1.993.900
07/09/2017 178,50 182,77 177,28 180,71 +1,31% 3,08% 2.985.300
06/09/2017 177,59 179,08 176,36 178,38 +0,93% 1,53% 2.242.300
05/09/2017 178,00 178,50 175,36 176,74 -1,10% 1,76% 1.959.900
01/09/2017 178,14 179,73 177,30 178,71 +0,53% 1,36% 2.431.900
31/08/2017 173,74 178,64 173,74 177,77 +2,37% 2,82% 3.977.500
30/08/2017 172,19 175,08 171,54 173,65 +0,82% 2,06% 2.310.900
29/08/2017 170,66 172,35 170,35 172,23 +0,26% 1,17% 1.483.000
28/08/2017 170,86 172,64 170,26 171,78 +1,20% 1,39% 2.359.500
25/08/2017 170,82 171,57 169,40 169,74 -0,12% 1,27% 1.510.800
24/08/2017 169,28 170,69 168,57 169,95 +0,56% 1,25% 1.922.400
23/08/2017 169,66 169,94 168,76 169,00 -0,63% 0,70% 1.279.400
22/08/2017 168,86 170,94 168,83 170,07 +1,14% 1,25% 1.933.500
21/08/2017 167,46 168,64 167,01 168,16 +0,52% 0,97% 1.533.300
18/08/2017 167,37 168,43 166,52 167,29 -0,31% 1,14% 1.741.900
17/08/2017 170,69 171,00 167,80 167,81 -2,09% 1,87% 2.630.600
16/08/2017 170,26 172,64 170,14 171,39 +0,79% 1,47% 1.618.800
15/08/2017 171,10 171,45 169,76 170,04 -0,95% 0,99% 1.956.300
14/08/2017 170,28 172,08 169,97 171,67 +1,32% 1,24% 1.915.800
11/08/2017 169,82 170,63 168,76 169,43 +0,19% 1,10% 1.571.600
10/08/2017 172,07 172,67 168,59 169,11 -2,56% 2,37% 3.443.800